Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke
It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, with no major safety issues reported after a y
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic
Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people
